Tourmaline Bio
Manufacturing · New York, United States · 51-200 Employees
View Company Info for Free
Overview
Headquarters
27 W 24th St Ste 702, New York City, New...Phone Number
(646) 481-9832Website
www.tourmalinebio.comRevenue
$61 MillionStock Symbol
TRMLIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Tourmaline Bio
Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.Explore more
Tourmaline Bio Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Tourmaline Bio your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Tourmaline Bio, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if Tourmaline Bio is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Tourmaline Bio
Check if Tourmaline Bio has recently received funding, and reach out quickly before it becomes old news!
Product Launch: Get notified when Tourmaline Bio launches new products
Earning: See what the market has to say on Tourmaline Bio recently announced quarterly report
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Tourmaline Bio has new funding data
Website visits: Recent activity has been detected on your website
Click to see if Tourmaline Bio had a recent Job posting/layoffs
Recommended Actions
Find VP level buyers at Tourmaline Bio
Find 2 more new buyers
Compare Similar Companies to Tourmaline Bio
Compare insights from companies similar to Tourmaline Bio, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Tourmaline Bio is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Tourmaline Bio is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Tourmaline Bio.
Tourmaline Bio Tech Stack
A closer look at the technologies used by Tourmaline Bio
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Executive Moves, Left Company
Left Company
Executive Move
Sandeep Kulkarni, Co-Founder & Chief Executive Officer, has recently left the organization and now serves as Chief Executive Officer for Zura Bio Limited.
Executive Moves, Left Company
Open Position
Tourmaline Bio News & Media
Novartis announces expiration of Tourmaline Bio tender offer
Basel, October 28 2025 - Novartis today announced that its previously announced tender offer (the “offer”) by Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48.00 per Share, in cash, without interest and subject to any applicable withholding, expiredNovartis announces expiration of Hart-Scott-Rodino waiting period of Tourmaline Bio tender offer
Basel, October 22, 2025 - Novartis today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”), in connection with Novartis’ previously announced tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48.00 per Share, in cash, without interest and subject to any applicableNovartis announces commencement of tender offer to acquire Tourmaline Bio
Basel, September 29, 2025 - Novartis today announced that Torino Merger Sub Inc., a Delaware corporation and an indirect wholly owned subsidiary of Novartis (“Purchaser”), has commenced a tender offer to acquire all of the outstanding shares of common stock, par value $0.0001 per share (the “Shares”), of Tourmaline Bio, Inc., a Delaware corporation (“Tourmaline”), at a price of $48 per Share, in cash, without interest and subject to any applicable withholding. Such offer is beingNovartis AG (NVS) Strengthens Cardiovascular Unit with Tourmaline Bio Acquisition
Novartis AG (NYSE:NVS) is one of the best defensive stocks to buy, according to Steve Cohen. On September 9, the company confirmed plans to acquire the New York-based pharmaceutical company Tourmaline Bio for $1.4 billion on a fully diluted basis. The acquisition paves the way for the company to gain access to pacibekitug, a candidate […]
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Tourmaline Bio
Sign Up For FreeTo access detailed company insights
Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. In doing so, we seek to develop assets medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.... Read More
